Please check your internet connection and try again.
# Piperacillin/Tazobactam
## Overview
Piperacillin/tazobactam is a combination penicillin-class antibiotic with beta-lactamase inhibitory activity. It is effective against a broad spectrum of aerobic and anaerobic Gram-positive and Gram-negative bacteria, including *Pseudomonas aeruginosa*.
## Primary Indications
* Complicated intra-abdominal infections
* Complicated skin and skin structure infections
* Community-acquired pneumonia
* Nosocomial pneumonia
* Febrile neutropenia
## Adult Dosing
* **General Dosing:** Typically 3.375 grams (piperacillin 3 g/tazobactam 0.375 g) every 6 hours or 4.5 grams (piperacillin 4 g/tazobactam 0.5 g) every 6 or 8 hours intravenously.
* **Severe Infections/Pseudomonas Coverage:** Higher doses, such as 4.5 grams every 6 hours, may be used. Doses up to 4.5 grams every 4 hours may be utilized for very severe infections, but this is less common.
* **Duration:** Typically 7 to 14 days, depending on infection severity and patient response.
## Pediatric Dosing
* **Children < 6 months:** Safety and efficacy not established. Dosing is complex and should be guided by expert clinical judgment and local protocols, often based on piperacillin component weight-based dosing.
* **Children ≥ 6 months:** Dosing is based on the piperacillin component:
* **General:** 25 mg piperacillin/3.125 mg tazobactam per kg per dose to 35 mg piperacillin/4.375 mg tazobactam per kg per dose intravenously every 6 hours.
* **Nosocomial Pneumonia/Febrile Neutropenia:** Up to 50 mg piperacillin/6.25 mg tazobactam per kg per dose intravenously every 6 hours.
* **Maximum Dose:** Generally not to exceed adult maximums. Consult specific pediatric guidelines for precise maximum dosages per administration and per day.
* **Duration:** Typically 7 to 14 days.
## Dose Adjustments
* **Renal Impairment:**
* CrCl > 40 mL/min: No dose adjustment needed.
* CrCl 20-40 mL/min: Reduce frequency to every 8 hours.
* CrCl < 20 mL/min: Reduce frequency to every 12 hours.
* Consider continuous infusion for patients with severe renal impairment to maintain adequate levels.
* **Hepatic Impairment:** No dose adjustment is typically recommended.
## Contraindications
* Hypersensitivity to piperacillin, tazobactam, other penicillins, or any component of the formulation.
## Adverse Effects
* **Common:** Diarrhea, nausea, vomiting, headache, rash, constipation, insomnia.
* **Serious:** *Clostridioides difficile*-associated diarrhea, hypersensitivity reactions (including anaphylaxis), seizures (especially with high doses or renal impairment), neutropenia, thrombocytopenia, elevated liver enzymes.
## Key Drug Interactions
* **Probenecid:** May decrease renal clearance of piperacillin and increase serum concentrations.
* **Neuromuscular Blocking Agents (e.g., vecuronium):** Piperacillin may prolong the neuromuscular blockade.
* **Warfarin:** May decrease the effect of warfarin; increased monitoring of INR is recommended.
* **Methotrexate:** May decrease serum methotrexate levels.
* **Bacteriostatic agents (e.g., tetracyclines, chloramphenicol):** May antagonize the bactericidal effect of piperacillin.
## Monitoring
* Monitor for signs and symptoms of hypersensitivity reactions.
* Monitor for signs and symptoms of *C. difficile*-associated diarrhea.
* Monitor renal function and electrolytes, especially in patients with renal impairment or receiving concomitant nephrotoxic agents.
* Monitor liver function tests periodically.
* Monitor complete blood counts, particularly during prolonged therapy, for hematologic changes.
* Monitor for effectiveness (resolution of fever, infection signs/symptoms).
## Clinical Pearls
* Piperacillin/tazobactam is a potent, broad-spectrum agent. Use judiciously to minimize resistance development.
* Ensure adequate hydration and electrolyte balance, especially with IV administration.
* Reconstituted solutions are stable for a limited time; follow manufacturer instructions for preparation and storage.
* The 4.5 g formulation contains 4 g piperacillin and 0.5 g tazobactam. The 3.375 g formulation contains 3 g piperacillin and 0.375 g tazobactam. Dosing must account for the total amount.
* For patients with CrCl < 20 mL/min, consider reducing the dose or extending the interval to every 8-12 hours. Continuous infusion strategies may be beneficial in severe renal impairment or critically ill patients.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the official prescribing information and current institutional guidelines for complete and up-to-date details before administering any medication.
